Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,39
KB0,43
PKN121121,70,75
Msft78,8878,891,26
IBM161,89161,90,62
DCX68,3368,36-0,84
PFE36,3636,370,36
20.10.2017 19:55:51
Indexy online
AD Index online
select
AD Index online
 

  • 20.10.2017 19:55:33
CymaBay (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
8,08 -1,22 -0,10 170 266
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.10.2017
Popis společnosti
Obecné informace
Název společnostiCymaBay Therapeutics Inc
TickerCBAY
Kmenové akcie:Ordinary Shares
RICCBAY.O
ISINUS23257D1037
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2015 21
Akcie v oběhu k 3.8.2017 43 756 968
MěnaUSD
Kontaktní informace
Ulice7999 Gateway Blvd Ste 130
MěstoNEWARK
PSČ94560-1188
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 102 938 800
Fax15102939090

Business Summary: CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
Financial Summary: BRIEF: For the six months ended 30 June 2017, CymaBay Therapeutics Inc revenues increased from $0K to $4.8M. Net loss increased 3% to $14.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other (expense) income, Net increase from $38K to $3.2M (expense), Interest Income decrease of 20% to $81K (income).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 20.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardRobert Wills628.10.20158.10.2015
Interim President, Interim Chief Executive Officer, Chief Financial OfficerSujal Shah426.12.2013
Senior Vice President, Chief Scientific OfficerCharles McWherter61
Vice President - Finance, Principal Financial Officer, Principal Accounting OfficerDaniel Menold4727.4.201727.4.2017
Vice President - Regulatory Affairs and Quality AssuranceKirk Rosemark4427.4.201527.4.2015
Chief Medical OfficerPol Boudes583.3.20143.3.2014